<DOC>
	<DOCNO>NCT02899598</DOCNO>
	<brief_summary>Neonatal thrombocytopenia isoimmunization maternal-fetal related maternal immunization fetal platelet antigens paternal origin present mother . It consider equivalent hemolytic disease newborn . The incidence disease 1 800-1000 birth . The severe form associate petechia , purpura cephalhematoma birth major risk cerebral hemorrhage ( 20 % 25 % case ) cause death child ( 15 % ) severe neurological trouble ( 15-30 % ) Biologic diagnosis require detection anti-platelet antibody maternal determination platelet phenotype genotypes two parent . The objective work develop specific molecular tool fetal platelet genotyping maternal blood . We particularly interested antigen HPA-1 , HPA-5 , HPA-3 HPA-4 . We evaluate sensitivity specificity test compare result obtain invasive sampling amniotic fluid . This prospective study assess technical diagnostic performance new molecular method noninvasive prenatal diagnosis platelet genotyping .</brief_summary>
	<brief_title>Genotyping Human Platelet Alloantigens : Non-invasive Prenatal Diagnosis</brief_title>
	<detailed_description>Neonatal thrombocytopenia isoimmunization maternal-fetal related maternal immunization fetal platelet antigens paternal origin present mother . It consider equivalent hemolytic disease newborn . The incidence disease 1 800-1000 birth . The severe form associate petechia , purpura cephalhematoma birth major risk cerebral hemorrhage ( 20 % 25 % case ) cause death child ( 15 % ) severe neurological trouble ( 15-30 % ) Biologic diagnosis require detection anti-platelet antibody maternal determination platelet phenotype genotypes two parent . When diagnose , genetic counseling couple future pregnancy necessary risk recurrence important severity increase number pregnancy . The risk depend nature paternal antigen , homozygous heterozygous . In case heterozygosity , prenatal diagnosis base fetal platelet genotyping invasive procedure ( amniocentesis chorionic villus sample ) associate risk fetal loss . The alloantibody responsible fetal damage direct platelet alloantigens : HPA system ( human platelet alloantigen ) . 24 alloantigens describe 12 biallelic polymorphism ( : frequent allele b rare allele ) divide 6 group ( HPA-1 , 2 , 3 , 4 , 5 , 15 ) . The genotype-phenotype correlation perform 22 24 alloantigens show antigenic polymorphism result presence SNP ( single nucleotide polymorphism- ) . In 1997 , Lo et al show presence 3-6 % fetal DNA maternal blood . This discovery lead development method non-invasive prenatal diagnosis : 1/ determination fetal Rhesus 2/ fetal sex real-time quantitative PCR . The objective work develop specific molecular tool fetal platelet genotyping maternal blood . We particularly interested antigen HPA-1 , HPA-5 , HPA-3 HPA-4 . We evaluate sensitivity specificity test compare result obtain invasive sampling amniotic fluid . This prospective study assess technical diagnostic performance new molecular method noninvasive prenatal diagnosis platelet genotyping .</detailed_description>
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Thrombocytopenia , Neonatal Alloimmune</mesh_term>
	<criteria>patient know risk platelet alloimmunization patient suspicion fetal cerebral hemorrhage advance ultrasound fetal MRI sign Twin pregnancy triple</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>